This company has been marked as potentially delisted and may not be actively trading. NASDAQ:RAIN Rain Oncology (RAIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsHeadlinesInsider TradesTrendsBuy This Stock About Rain Oncology Stock (NASDAQ:RAIN) 30 days 90 days 365 days Advanced Chart Get Rain Oncology alerts:Sign Up Key Stats Today's Range$2.61▼$2.9350-Day Range$1.20▼$1.2452-Week Range$0.82▼$11.32Volume24,434 shsAverage Volume32,376 shsMarket Capitalization$16.01 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAs of January 26, 2024, operates as a subsidiary of Pathos AI, Inc.Read More… Receive RAIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address RAIN Stock News HeadlinesToronto runners brave rain to raise roughly $23,000 for cancer fightMarch 15, 2025 | msn.com13-year-old rain cancer survivor calls out Democrats: ‘Stop being mean to Trump’March 8, 2025 | msn.comGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.April 25, 2025 | Weiss Ratings (Ad)Brain cancer: Recognising tumour symptoms, risk factors and seeking treatmentNovember 24, 2024 | msn.comNewfoundland man electrocuted by downed power line, two women injuredNovember 11, 2024 | msn.comKing Charles III and Kate attend remembrance events as both slowly return to dutyNovember 11, 2024 | msn.comPrince William describes family's ‘brutal’ year as wife and father faced cancer treatmentNovember 8, 2024 | msn.comThe Eras Tour kept me going during my breast cancer treatmentNovember 8, 2024 | theglobeandmail.comSee More Headlines RAIN Stock Analysis - Frequently Asked Questions How were Rain Oncology's earnings last quarter? Rain Oncology Inc. (NASDAQ:RAIN) announced its earnings results on Wednesday, November, 10th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.06. When did Rain Oncology IPO? Rain Oncology (RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities served as the underwriters for the IPO. What other stocks do shareholders of Rain Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Rain Oncology investors own include CRISPR Therapeutics (CRSP), Meta Platforms (META), UiPath (PATH), Recursion Pharmaceuticals (RXRX), Alibaba Group (BABA), NVIDIA (NVDA) and Company Calendar Last Earnings11/10/2021Today4/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Holding & other investment offices Sub-IndustryN/A Current SymbolNASDAQ:RAIN CIK1724979 Webwww.rainthera.com Phone510-953-5559FaxN/AEmployees63Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.10 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-9.51% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.39 per share Price / Cash Flow7.41 Book Value($0.69) per share Price / Book-4.19Miscellaneous Outstanding Shares5,540,000Free Float4,574,000Market Cap$16.01 million OptionableNo Data Beta-0.11 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:RAIN) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rain Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rain Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
